80% of pancreatic cancers are diagnosed at Stage III or IV — when surgery is no longer possible. Not because early-stage cancer is invisible. But because the tools we use to find it weren't built for where the cancer actually is. Lumicede was founded to change that.

The Proximal Advantage

While blood-based tests suffer from systemic dilution, and tissue biopsies struggle with small lesions, duodenal-pancreatic fluid tells a different story. It directly bathes the tumor site. It carries high concentrations of tumor-derived exosomes — before dilution, before degradation. Lumicede™ captures that signal.

Lumicede™ — Built for the EUS Suite An adjunctive diagnostic test for patients undergoing Endoscopic Ultrasound (EUS) who are suspected of or require differentiation of pancreatic cancer (Stage 1-4). Integrated into the existing EUS workflow. No additional procedures. No proprietary equipment required.

Our Vision

A world where a pancreatic cancer diagnosis — at Stage I, not Stage IV — is the expected outcome, not the lucky exception. We are building the platform that makes that world possible. Starting in the endoscopy suite. Today.

For Partnership & Investment Inquiries: contact@lumicede.com